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ABSTRACT 
The management of an acute coronary syndrome (ACS) in a patient with existing atrial fibrillation 
(AF) often presents a management dilemma both in the acute phase and post-ACS, since the majority 
of AF patients will already be receiving oral anticoagulation (OAC) for stroke prevention and will 
require further antithrombotic treatment (ATT) to reduce the risk of in-stent thrombosis or recurrent 
cardiac events.  Current practice recommendations are based largely on consensus option as there is 
limited evidence from randomised controlled trials.  Prior to the launch of the new European Heart 
Rhythm Association (EHRA) consensus document, a survey was undertaken to examine current 
clinical management of these patients across centres in Europe.  Forty-seven centres submitted valid 
responses, with the majority (70.2%) being university hospitals.  This EHRA survey demonstrated 
overall the management of ACS in AF patients is consistent with the available guidance.  Most 
centres would use triple therapy for a short duration (4 weeks) and predominantly utilise a strategy of 
OAC (VKA or NOAC) plus aspirin and clopidogrel, followed by dual therapy ((N)OAC plus 
clopidogrel) until 12-months post-PCI, followed by (N)OAC monotherapy indefinitely.  Where 
NOAC was used in combination with antiplatelet(s), the lower dose of the respective NOAC was 
preferred, in accordance with current recommendations. 
  
INTRODUCTION 
Acute coronary syndrome (ACS) commonly occurs in patients with atrial fibrillation (AF), which 
often requires percutaneous coronary intervention (PCI) typically including stenting.  However, the 
occurrence of ST segment elevation myocardial infarction (STEMI) or a non-ST-segment elevation 
acute coronary syndrome (NSTE-ACS) in a patient with existing AF often presents a management 
dilemma both in the acute phase and post-ACS, since the majority of AF patients will likely already 
be receiving oral anticoagulation (OAC) for stroke prevention and will require further antithrombotic 
treatment (ATT) to reduce the risk of in-stent thrombosis or recurrent cardiac events.  This requires a 
delicate balancing of the risk of thromboembolic and atherothrombotic events against the increased 
chance of bleeding, and should be undertaken on an individual patient basis (1-2). 
 
In 2014, a joint consensus document was published to provide guidance on the management of ATT 
in AF patients presenting with ACS and/or undergoing PCI (3) in the setting of limited available 
evidence from randomised controlled trials (RCTs) about the optimal antithrombotic strategy post-
ACS in patients with AF.  Since 2014, further observational studies and RCT data has been published 
and non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly used.  In addition, 
there are more recent European guidelines on the management of AF (4) and management of STEMI 
(5), focussed updates on dual antiplatelet therapy in coronary artery disease (6) and the European 
Heart Rhythm Association (EHRA) NOAC practical guide, (7) (which includes a chapter on the 
management of AF in patients with coronary artery disease).  Therefore, the 2014 consensus guidance 
on the management of AF patients with ACS was updated in 2018 (8) and EHRA conducted a survey 
to capture the current management of ACS in AF patients in Europe prior to the launch of the new 
consensus document. 
 
METHODS AND RESULTS 
The EHRA electrophysiology research network was utilised to distribute a 22-item questionnaire 
survey on-line between 26 July and 7 September 2018.  Fifty-seven centres responded, and 47 unique 
responses were included in the analyses (3 were duplicate responses and 7 were blank).  Where 
complete data was not available the number of responses is indicated and the proportion reported as a 
percentage of the available answers.  Most of the 47 centres were university hospitals (70.2%), with 9 
(19.2%) non-university hospitals and 5 (10.6%) private hospitals.  Almost all centres (95.7%) had a 
24-hour, 365-day primary percutaneous coronary intervention (PCI service), with the majority 
(66.0%) performing >1000 PCIs annually, 13 (27.7%) with between 501-1000 PCIs per year, 1 
(2.1%) centre each with 101-500 or 1-100 PCIs annually, and only 1 centre where no such procedures 
were undertaken.  Only one centre reported no experience of managing an AF patient on a non-
vitamin K antagonist oral anticoagulant (NOAC) with an ACS over the previous 12 months. 
 
I. Acute management of AF patients on OAC presenting with an ACS 
ST-elevation myocardial infarction within an optimal timeframe for primary PCI 
Among STEMI patients on a vitamin K antagonist (VKA), most (91.5%) centres would proceed with 
a primary PCI on uninterrupted VKA regardless of the INR value, however, 4 (8.5%) centres would 
only proceed if the INR value was below a certain level, although there was no consensus among the 
respondents about the cut-off INR value (ranging from 2.5-3.5).  Among STEMI patients on a NOAC, 
31/46 (67.4%) centres would proceed with primary PCI without NOAC interruption, whereas 15/46 
(32.6%) centres would temporarily discontinue NOAC therapy before the PCI. 
 
Figure 1a presents the pre-procedural loading with antiplatelet drugs among STEMI patients with AF 
receiving VKA or NOAC therapy; respondents were able to choose multiple responses.  A similar 
pattern of pre- procedural anti-thrombotic regimens were employed regardless of the presence of 
VKA or NOAC at presentation.  Dual antiplatelet therapy was the most commonly selected option, 
added to VKA by 28/46 (60.9%) centres and to NOAC by 26/46 (56.5%) centres (Figure 1a). Aspirin 
plus clopidogrel was the most frequently used dual antiplatelet regimen in combination with VKA 
(19/46 (41.3%) centres), or a NOAC (24/46 (51.2%) centres).  Addition of aspirin only or clopidogrel 
only to VKA was employed in 6/46 (13.0%) and 10/46 (21.7%) centres, and to a NOAC in 4/46 
(8/7%) and 10/46 (21.7%) centres, respectively.  Pre-procedural use of either ticagrelor or prasugel 
alone or in combination with aspirin was less often preferred, particularly in addition to NOAC 
(prasugel or ticagrelor alone (n=1); aspirin plus ticagrelor (n=2)), while more centres would utilise the 
newer P2Y12 inhibitors in addition to VKA (prasugel or ticagrelor alone (n=2); aspirin plus prasugel 
(n=2); aspirin plus ticagrelor (n=7)). Very few centres used parenteral anticoagulation peri-
procedurally in addition to VKA or NOAC (Figure 1b).  Unfractionated heparin was the most 
commonly selected option, added to VKA by 6/46 (13.0%) centres and to NOAC by 7/46 (15.2%), 
with 5 (10.9%) centres adding GPIIb/IIIa inhibitors to either VKA or NOAC only in selected patients. 
 
Insert Figures 1a and 1b here 
 
Non-ST-segment elevation ACS 
The management of a NSTE-ACS in AF patients was very similar regardless of the existing VKA or 
NOAC therapy (Figure 2).  The majority of centres would proceed with the PCI within the first 24 
hours after admission; more specifically, 40/46 centres (87.0%) would carry out PCI within the first 
24 hours in patients taking a VKA, and 41/45 centres (91.1%) would do so in patient taking a NOAC, 
whereas 6/46 (13.0%) and 5/45 centres (11.1%) would postpone the PCI for as long as possible in 
patients taking VKA or NOAC, respectively.  Bare-metal stents (BMS) were preferred over drug-
eluting stents (DES) in only 8/46 (17.4%) and 7/45 centres (15.6%) among patients on VKA and 
NOAC, respectively.  Risk of bleeding was taken into consideration when choosing alternative 
treatment strategies.  Seven centres would consider angioplasty without stent implantation, and five 
centres would consider bypass surgery instead of PCI, in patients at high risk of bleeding. 
 
Insert Figure 2 here 
 
Preferred pre- and peri-procedural anti-thrombotic strategies are shown in Figure 3a.  Almost half of 
the centres (21/46, 46.7%) would add dual antiplatelet therapy (aspirin plus clopidogrel) to OAC, 
while only a few centres would use aspirin in combination with either ticagrelor (1 centre) or prasugel 
(2 centres).  Very few centres used parenteral anticoagulation peri-procedurally in addition to OAC 
(Figure 3b); three would use enoxaparin or other low molecular weight heparin and five would use 
unfractionated heparin, with four centres utilising GPIIb/IIIa inhibitors only in selected patients. 
 
Insert Figures 3a and 3b here 
 
II. Post-procedural management of AF patients undergoing primary PCI for ACS  
Patients with CHA2DS2-VASc score ≥2 and a HAS-BLED score of 1 
In patients with AF who have undergone a primary PCI for ACS, initial post-intervention 
antithrombotic options differed depending on the patient’s risk of stroke and risk of bleeding.  Among 
those with a CHA2DS2-VASc score ≥2 and a HAS-BLED score of 1, triple therapy (OAC plus dual 
antiplatelet therapy with aspirin and clopidogrel) was preferred by the majority of centres (36/45, 
80.0% for those on VKA at baseline and 34/45 centres, 75.6% for patients on NOAC at baseline) (see 
Figure 4a). Most centres would continue the OAC that was in place prior to the PCI (100% for NOAC 
and 27/36 centres, 75.0% for VKA).  
However, centres differed in the duration of triple therapy, with 12/27 (44.4%) and 15/34 centres 
(44.1%) opting for 4 weeks of triple therapy in patients taking VKA and NOAC at baseline, 
respectively, whereas 15/27 (55.6%) and 19/34 centres (55.9%) would undertake 6 months of triple 
therapy in patients taking VKA or NOAC at baseline, respectively.  Two out of 45 (4.4%) and 6/45 
centres (13.3%) would add clopidogrel alone to the pre-existing OAC (VKA and NOAC, 
respectively).   
Among patients who were taking VKA prior to their PCI, one-third of centres would consider 
switching them to a NOAC post-PCI (in combination with either DAPT or clopidogrel only), with a 
preference for a short duration of triple therapy (4 weeks), whereas only one centre would consider 
switching a patient from a NOAC to VKA plus clopidogrel (see Figure 4a).  Aspirin alone in 
combination with VKA was not chosen by any centre as a treatment option; only 1 centre would give 
NOAC and aspirin.  No centres would use ticagrelor or prasugel in combination with OAC (either 
VKA or NOAC) post-PCI. 
 
Insert Figure 4a here 
 
After completing the initial period of either dual or triple therapy, most centres (34/45, 75.6%) would 
continue dual therapy (OAC plus one antiplatelet drug) for 12-months post-PCI and 6/45 (13.3%) 
centres would continue dual therapy indefinitely (see Figure 4b).  There did not appear to be a clear 
preference for VKA or NOAC as the OAC of choice in this dual therapy regimen, although 
clopidogrel was the preferred antiplatelet agent in combination with OAC (either VKA or NOAC).  
No centre would continue triple therapy until 12-months post-PCI however, 7/45 centres (15.6%) 
would choose OAC monotherapy (most with NOAC) after the initial period of either dual or triple 
therapy (see Figure 4b).  
 
Insert Figure 4b here 
 
Patients with CHA2DS2-VASc score of 4 and a HAS-BLED score of 3 
Among AF patients with a CHA2DS2-VASc score of 4 and a HAS-BLED score of 3 (higher risk of 
stroke and higher risk of bleeding) the preferred initial post-PCI antithrombotic regimen was more 
variable (see Figure 4c).  Triple therapy for 4 weeks was preferred by most centres (26/45 (57.8%) 
with VKA and 28/45 (62.2%) with NOAC), with OAC in combination with aspirin and clopidogrel 
being most commonly chosen; the responses differed slightly depending on which OAC patients were 
receiving prior to PCI (see Figure 4c).  Use of the newer P2Y12 inhibitors (prasugel and ticagrelor) in 
combination with aspirin and OAC was selected as an option by very few centres (2 centres in 
combination with VKA and 1 with NOAC).  Longer-term use of triple therapy (for 6 months) was 
selected by 7 (15.6%) centres, with dual therapy (OAC plus antiplatelet) for 4 weeks chosen by 
several centres (16/45 (35.6%) with VKA and 18/45 (40.0%) with NOAC), with OAC in combination 
with clopidogrel preferred.  
 
Insert Figure 4c here 
 
After completing the initial period of either dual or triple therapy, most centres would continue dual 
therapy until 12 months post-PCI in patients at high risk of stroke and high risk of bleeding, with the 
majority selecting OAC (VKA or NOAC) plus clopidogrel (see Figure 4d).  One centre would 
continue dual therapy indefinitely.  No centres would continue triple therapy until 12 months post-
PCI.  Six out of 45 (13.3%) and 8/45 (17.8%) centres, respectively would continue VKA or NOAC 
alone and 7/45 (15.6%) would switch patients from a VKA to NOAC. 
 
Insert Figure 4d here 
 
If prescribing a NOAC in combination with either mono- or dual antiplatelet therapy following PCI in 
patients with normal renal function,, most (32/45 (71.1%)) centres would choose dabigatran 110mg 
bid, regardless of the CHA2DS2-VASc score and HAS-BLED score; the lower dose of each of the 
NOACs was preferred over the standard dose when given in combination with antiplatelet therapy 
(see Figures 5). 
 
Insert Figure 5 here 
 
DISCUSSION 
The main findings of this survey were that most centres would use triple therapy for a short duration 
(4 weeks) and predominantly utilise a strategy of OAC (VKA or NOAC) plus aspirin and clopidogrel, 
followed by dual therapy ((N)OAC plus clopidogrel) until 12-months post-PCI, followed by (N)OAC 
monotherapy indefinitely.  Where NOAC was used, the lower dose of the respective NOAC was 
preferred, in accordance to current recommendations. 
 
Acute management of a ST-elevation myocardial infarction within an optimal timeframe for 
primary PCI in AF patients on oral anticoagulation therapy 
The majority (91.5%) of respondents would proceed to PCI without interruption of the baseline OAC 
which is in accordance with current clinical guidelines (4-5, 7-9).  However, respondents were more 
likely to choose this approach when the patient was on VKA at the time of the ACS; approximately 
one-third (32.6%) of respondents would temporarily discontinue the NOAC before proceeding with 
PCI compared to only 8.5% discontinuing VKA.  This practice of pre-procedural discontinuation of 
the NOAC reflects the guidance given in the 2018 NOAC practical guide (7) and is similar to clinical 
practice reported in the previous EHRA survey on this aspect of acute management of ACS in an AF 
patient (10). 
 
The choice of pre-procedural antithrombotic strategies was heterogeneous but the pattern was similar 
regardless of the presence of VKA or NOAC at presentation, with dual antiplatelet therapy consisting 
of aspirin and clopidogrel being the most preferred combination.  The 2017 dual antiplatelet therapy 
focused update (6), 2016 AF guidelines (4) and 2018 NOAC practical guide (7) and 2018 EHRA 
consensus (8) discourages use of prasugel or ticagrelor as components of a triple therapy regimen, yet 
a few centres would utilise them for triple therapy, more often in combination with VKA than NOAC.  
The current guidance (4, 6-8) does not discount the use of one of the newer P2Y12 inhibitor in 
combination with OAC (VKA or NOAC), in patients at higher risk of thrombotic complications, 
which may explain why a few centres would utilise prasugel or ticagrelor together with (N)OAC.  In 
addition, parenteral anticoagulation with unfractionated heparin, enoxaparin or bivalirudin (but not 
fondaparinux) is recommended in the management of acute STEMI (7-9) and is reflected in the 
responses of this survey.  Use of GPIIb/IIIa inhibitors is only advocated in bail-out situations (7) and 
this recommendation appears to be adhered to as respondents would only use these drugs in selected 
patients. 
 
Acute management of a non-ST-segment elevation ACS in AF patients on oral anticoagulation 
therapy 
Guidance on the management of a NSTE-ACS is highly dependent on the individual risk profile of 
the patient (11).  This survey demonstrates similar management of a NSTE-ACS in AF patients 
regardless of the existing (N)OAC therapy, which is contrary to current recommendations (4-7).  The 
majority of centres would proceed with the PCI within 24-hours, with only a few (11-13%) opting to 
postpone the PCI for as long as possible.  However, current recommendations (7), advocate stopping 
the NOAC at admission, delaying PCI, and starting fondaparinux (preferred) or low-molecular weight 
heparin (≥12 hours after last NOAC dose) in non-urgent cases, whilst urgent cases should be treated 
as for STEMI (7).  Bare metal stents are no longer advocated to shorten the length of time on dual or 
triple therapy post-PCI, however, a few (16-17%) centres would always use BMS, rather than 
employing contemporary DES which are now preferred (5, 7-8).  A few centres would employ 
angioplasty without stenting or bypass surgery in patients at high risk of bleeding but this approach is 
no longer advocated. 
 
Dual antiplatelet therapy is recommended for all NSTE-ACS on presentation regardless of subsequent 
invasive procedure or not (12).  However, slightly less than half (46.7%) of the centres would add 
dual antiplatelet therapy (aspirin and clopidogrel) to OAC pre-procedurally, with only 1-2 centres 
opting to use aspirin in combination with either ticagrelor or prasugel.  
 
Antithrombotic strategies (dual or triple therapy) post-PCI in AF patients 
Current recommendations on the duration of triple therapy and antithrombotic options differ 
depending on the patient’s risk of stroke, atherothrombotic risk, risk of bleeding and stent type (newer 
generation DES vs. other stent types) (7, 11).  Although the focused update of the ESC (6) 
recommends triple therapy (OAC plus dual antiplatelet therapy) for all AF patients following ACS 
who undergo PCI with stenting, followed by dual therapy (ideally (N)OAC plus clopidogrel (or 
aspirin/prasugel/ticagrelor)), the data show no additional benefit over and above dual therapy but 
confer a higher bleeding risk (13-15) and therefore the duration should be kept as short as possible. 
Consequently the 2018 EHRA practical guide on NOACs (7) mentions the option of using triple 
therapy (aspirin, ticagrelor, and OAC) for only 1-7 days (until discharge) and then dual therapy 
(ticagrelor [or clopidogrel, or aspirin] plus OAC) for 12 months.  However, in this EHRA survey, 
triple therapy was preferred by most centres regardless of the stroke and bleeding risk, although a 
shorter duration (4 weeks) was favoured in those at higher risk of bleeding. 
 
With regards to dual antithrombotic therapy, clopidogrel in combination with OAC was also a popular 
initial ATT strategy. Among patients with a CHA2DS2-VASc score ≥2 and a HAS-BLED score of 1, 
aspirin alone in combination with OAC was only selected by one centre (NOAC plus aspirin) and no 
centres would use ticagrelor or prasugel in combination with (N)OAC post-PCI, which is in line with 
current clinical recommendation (NOAC or VKA plus clopidogrel preferred) (7-8).    Two 
randomised controlled trials, PIONEER AF-PCI (16) and RE-DUAL PCI (17) compared dual therapy 
(NOAC (two different doses) plus P2Y12 inhibitor) to VKA-based triple therapy (VKA, P2Y12 
inhibitor and low-dose aspirin) and demonstrated a significant reduction in clinically significant 
bleeding (16) or major or clinically relevant non-major bleeding with the NOAC plus P2Y12 inhibitor 
dual therapy options compared to triple therapy.   
 
The results of this EHRA survey suggest that the practice of dual ATT with a NOAC and P2Y12 
inhibitor regimen is infrequently employed in clinical practice.  There are currently two on-going 
randomised controlled trials, AUGUSTUS (18) and ENTRUST AF PCI (19) which are examining the 
effect of apixaban or edoxaban, respectively, versus warfarin in combination with either single or dual 
antiplatelet therapy in AF patients with ACS and/or PCI but again both are underpowered for efficacy. 
A recent systematic review and meta-analysis of 4 published randomized controlled trials of  OAC 
and antiplatelet therapy in AF patients undergoing PCI (WOEST, ISAR-TRIPLE, PIONEER-A-PCI, 
and REDUAL-PCI) (20) demonstrated a significant reduction in TIMI major or minor bleeding with 
dual ATT compared to triple ATT [Hazard ratio (HR) 0.53, 95% credible interval (CrI) 0.36-0.85)], 
with a similar risk of major adverse cardiovascular events with dual and triple ATT (HR 0.85, 95% 
CrI 0.48-1.29).  There is still no definitive answer regarding the efficacy of triple therapy versus dual 
ATT (OAC plus APT) or the optimal duration for triple therapy. 
 
After completing the initial period of either dual or triple therapy, three-quarters of centres would 
continue dual therapy until 12 months post-PCI, with most selecting (N)OAC plus clopidogrel, in 
accordance with clinical guidance (4-9), with seven (15.6%) centres continuing either VKA or NOAC 
alone 12-months post-PCI, while one centre would continue dual therapy indefinitely.  This 
demonstrates that respondents’ clinical practice reflects implementation of current recommendations. 
 
There is currently no recommendation to switch patients from a NOAC to a VKA after PCI (7), and 
only one centre reported this strategy, however, one-third of centres would consider switching a 
patient from VKA to NOAC post-PCI (in combination with either DAPT or clopidogrel). 
 
Choice of NOAC 
This survey also revealed that centres adhere to current recommendations (4-9) in prescribing the 
lower dose of each NOAC tested in the RCTs for stroke prevention in AF when a NOAC is utilised in 
combination with aspirin or clopidogrel, with dabigatran 110mg bid favoured, which might reflect the 
availability of an antidote. 
 
The past and the present 
The present survey reflects changes in clinical practice since the previous EHRA survey in 2014. (10) 
The current survey demonstrates the growing confidence of cardiologists in performing a primary PCI 
without interrupting the NOAC in patients presenting with STEMI (39% vs. 67.4%), and a dramatic 
reduction in the use of BMS (from 54.1% in 2014 to 16-17% in 2018) in patients presenting with ACS 
and pre- and peri-procedural dual antiplatelet therapy loading (75.6% in 2014 compared to 46.7% in 
2018). There are also striking differences noted in the duration of triple and dual ATT in patients with 
AF after PCI. From the 2014 survey, most (83.8%) centres would continue triple therapy for 3-6 
months for a drug-eluting stent, with 16.2% continuing triple therapy for 9-12 months.  In contrast, 
currently the majority (57.8-62.2%) of centres would utilise triple therapy for a shorter duration (4 
weeks) for patients at high risk of stroke and bleeding, with a smaller proportion continuing triple 
therapy for a maximum of 6 months. Among patients at lower risk of bleeding (and stroke), the 
current survey suggests that the majority (56%) would continue triple therapy for 6 months.  
Regarding the current preferred duration of dual therapy after PCI, around three-quarters of the 
centres would continue this for up to 12 months, with 13.3% and 2.2% continuing this indefinitely 
among those at low and high risk of bleeding, respectively.  This demonstrates an inversion of the 
clinical preference and practice of 2014, where 21.6% of centres would continue dual therapy for up 
to 12 months and 62.2% continuing this indefinitely, perhaps reflecting a more individualised 
therapeutic approach based on bleeding risk currently.  
 
Limitations 
The overall response rate was low; only 33% participated.  In addition, the majority (70.2%) of 
responders were from university hospitals and thus the results of this EHRA survey may not be 
representative of current clinical practice across Europe.  Those who respond to on-line surveys may 
be more knowledgeable about current clinical recommendations (response bias).  In addition, they 
may be reporting the ‘correct’ answer which may not reflect their actual clinical practice (social 
desirability bias) as knowledge is not always translated into action/practice. 
 
CONCLUSIONS 
This EHRA survey demonstrates that the management of ACS in AF patients is generally in line with 
the available guidelines Antithrombotic management of ACS in AF patients is a highly debated topic 
and the optimal combination of OAC and antiplatelet(s) and the duration of therapy remain 
unanswered. Further research is needed to inform the management of such patients, and the ongoing 
trials will contribute to filling at least some of the knowledge gaps.  
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Figure legends 
 
Figure 1a: Pre-procedural loading with antiplatelet therapy among STEMI patients with AF receiving 
VKA or NOAC therapy prior to admission 
Three respondents indicated they did not perform PCI and therefore could not answer this question 
 
Figure 1b: Peri-procedural parenteral anticoagulation among STEMI patients with AF receiving 
VKA or NOAC therapy prior to admission  
Three respondents indicated they did not perform PCI and therefore could not answer this question 
 
Figure 2: Acute management of non-ST-segment elevation ACS among patients with AF receiving 
VKA or NOAC therapy 
 
Figure 3a: Pre--procedural loading with antiplatelet therapy among non-ST-segment elevation ACS 
among patients with AF receiving OAC (either VKA or NOAC) prior to admission 
Three respondents indicated they did not perform PCI and therefore could not answer this question 
 
Figure 3b: Peri-procedural parenteral anticoagulation among non-ST-segment elevation ACS among 
patients with AF receiving OAC (either VKA or NOAC) prior to admission 
Three respondents indicated they did not perform PCI and therefore could not answer this question 
 
Figure 4a: Initial post-PCI antithrombotic therapy among patients with AF and a CHA2DS2-VASc 
score ≥2 and a HAS-BLED score of 1, receiving either VKA or NOAC therapy prior to PCI 
 
Figure 4b: Longer-term antithrombotic therapy post-PCI (after the initial phase) among patients with 
AF and a CHA2DS2-VASc score ≥2 and a HAS-BLED score of 1, who received either VKA or 
NOAC therapy prior to PCI 
 
Figure 4c: Initial post-PCI antithrombotic therapy among patients with AF and a CHA2DS2-VASc 
score of 4 and a HAS-BLED score of 3, receiving either VKA or NOAC therapy prior to PCI 
 
Figure 4d: Longer-term antithrombotic therapy treatment post-PCI (after the initial phase) among 
patients with AF and a CHA2DS2-VASc score of 4 and a HAS-BLED score of 3, receiving either 
VKA or NOAC therapy prior to PCI  
 
Figure 5: Preferred NOAC following a PCI when given in combination with mono- or dual 
antiplatelet therapy for AF patients with normal renal function (CrCl ≥75 mL/min) and a CHA2DS2-
VASc score ≥2 and a HAS-BLED score of 1 (darker colour) or CHA2DS2-VASc score of 4 and a 
HAS-BLED score of 3 (lighter colour) 
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